All Stories

  1. Discordant Health Implications and Molecular Mechanisms of Vitamin D in Clinical and Preclinical Studies of Prostate Cancer: A Critical Appraisal of the Literature Data

    Article • International Journal of Molecular Sciences, May 2024, MDPI AG

    Professor Klaus Jung

  2. Grainyhead-like 2 Deficiency and Kidney Cyst Growth in a Mouse Model

    Article • Journal of the American Society of Nephrology, April 2024, Wolters Kluwer Health

    Zeliha Yesim Yurtdas, Professor Klaus Jung

  3. Clinical implications of AGR2 in primary prostate cancer: Results from a large‐scale study

    Article • Apmis, January 2024, Wiley

    Professor Klaus Jung

  4. Data from Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  5. Supplementary file captions from Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  6. Table S3 from Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  7. Figure S1 from Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  8. Figure S2 from Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  9. Figure S3 from Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  10. Table S2 from Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  11. Table S1 from Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  12. Table S4 from Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma

    Article • March 2023, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  13. Prostate volume and its influence on clinical parameters in prostate cancer detection

    Article • Journal of Clinical Laboratory Analysis, January 2023, Wiley

    Professor Klaus Jung

  14. Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy

    Article • Cancers, March 2022, MDPI AG

    Professor Klaus Jung

  15. CD103+ Tissue Resident T-Lymphocytes Accumulate in Lung Metastases and Are Correlated with Poor Prognosis in ccRCC

    Article • Cancers, March 2022, MDPI AG

    Professor Klaus Jung

  16. Comparison of PHI and PHI Density for Prostate Cancer Detection in a Large Retrospective Caucasian Cohort

    Article • Urologia Internationalis, August 2021, Karger Publishers

    Professor Klaus Jung

  17. The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p

    Article • Cancer Biomarkers, April 2021, IOS Press

    Professor Klaus Jung

  18. PHI density prospectively improves prostate cancer detection

    Article • World Journal of Urology, January 2021, Springer Science + Business Media

    Professor Klaus Jung

  19. Endocytosis-Mediated Replenishment of Amino Acids Favors Cancer Cell Proliferation and Survival in Chromophobe Renal Cell Carcinoma

    Article • Cancer Research, December 2020, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  20. Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors

    Article • International Journal of Molecular Sciences, October 2020, MDPI AG

    Professor Klaus Jung

  21. Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of KRT5, KRT20, and ERBB2 in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy

    Article • International Journal of Molecular Sciences, October 2020, MDPI AG

    Professor Klaus Jung

  22. Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma

    Article • Cancer Research, September 2020, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  23. Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients

    Article • Nature Communications, February 2020, Springer Science + Business Media

    Professor Klaus Jung

  24. Limited utility of qPCR-based detection of tumor-specific circulating mRNAs in whole blood from clear cell renal cell carcinoma patients

    Article • BMC Urology, February 2020, Springer Science + Business Media

    Professor Klaus Jung

  25. Instability of circular RNAs in clinical tissue samples impairs their reliable expression analysis using RT-qPCR: from the myth of their advantage as biomarkers to reality

    Article • Theranostics, January 2020, Ivyspring International Publisher

    Professor Klaus Jung

  26. A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature

    Article • Cancers, October 2019, MDPI AG

    Professor Klaus Jung

  27. Circular RNAs in Clear Cell Renal Cell Carcinoma: Their Microarray-Based Identification, Analytical Validation, and Potential Use in a Clinico-Genomic Model to Improve Prognostic Accuracy

    Article • Cancers, September 2019, MDPI AG

    Professor Klaus Jung

  28. Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation

    Article • Cancers, September 2019, MDPI AG

    Professor Klaus Jung

  29. Plasma miR‑15b‑5p and miR‑590‑5p for distinguishing patients with bladder cancer from healthy individuals

    Article • Oncology Reports, July 2019, Spandidos Publications

    Professor Klaus Jung

  30. Lymphatic micrometastases predict biochemical recurrence in patients undergoing radical prostatectomy and pelvic lymph node dissection for prostate cancer

    Article • Aktuelle Urologie, March 2019, Thieme Publishing Group

    Professor Klaus Jung

  31. Apelin and apelin receptor expression in renal cell carcinoma

    Article • British Journal of Cancer, February 2019, Springer Science + Business Media

    Professor Klaus Jung

  32. Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear-Cell and Papillary Renal-Cell Carcinoma

    Article • Clinical Genitourinary Cancer, February 2019, Elsevier

    Professor Klaus Jung

  33. Circular RNAs: a new class of biomarkers as a rising interest in laboratory medicine

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), November 2018, De Gruyter

    Professor Klaus Jung

  34. miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma

    Article • Cancers, September 2018, MDPI AG

    Professor Klaus Jung

  35. Gegendarstellung zu: PSA‑Screening

    Article • Der Urologe, June 2018, Springer Science + Business Media

    Professor Klaus Jung

  36. Circulating miRNAs in blood and urine as diagnostic and prognostic biomarkers for bladder cancer: an update in 2017

    Article • Biomarkers in Medicine, June 2018, Future Medicine

    Professor Klaus Jung

  37. Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder

    Article • International Journal of Molecular Sciences, May 2018, MDPI AG

    Professor Klaus Jung

  38. The value of digital rectal examination in clinical practice

    Article • AME Medical Journal, March 2018, AME Publishing Company

    Professor Klaus Jung

  39. Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role

    Article • The Journal of Urology, February 2018, Wolters Kluwer Health

    Professor Klaus Jung

  40. Renal oncocytoma characterized by the defective complex I of the respiratory chain boosts the synthesis of the ROS scavenger glutathione

    Article • Oncotarget, November 2017, Impact Journals, LLC

    Professor Klaus Jung

  41. Advances in Biomarkers for PCa Diagnostics and Prognostics—A Way towards Personalized Medicine

    Article • International Journal of Molecular Sciences, October 2017, MDPI AG

    Professor Klaus Jung

  42. Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies?

    Article • International Journal of Molecular Sciences, September 2017, MDPI AG

    Professor Klaus Jung

  43. miR-199a-3p and miR-214-3p improve the overall survival prediction of muscle-invasive bladder cancer patients after radical cystectomy

    Article • Cancer Medicine, September 2017, Wiley

    Professor Klaus Jung, Dr. Thorsten Ecke

  44. Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression

    Article • Oncotarget, August 2017, Impact Journals, LLC

    Professor Klaus Jung

  45. Punicalagin, a polyphenol from pomegranate fruit, induces growth inhibition and apoptosis in human PC-3 and LNCaP cells

    Article • Chemico-Biological Interactions, August 2017, Elsevier

    Professor Klaus Jung

  46. Effects of octenidine mouth rinse on apoptosis and necrosis of human fibroblasts and epithelial cells – an in vitro study

    Article • Drug and Chemical Toxicology, July 2017, Taylor & Francis

    Professor Klaus Jung

  47. Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA

    Article • International Journal of Molecular Sciences, May 2017, MDPI AG

    Professor Klaus Jung

  48. The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients

    Article • Oncotarget, April 2017, Impact Journals, LLC

    Professor Klaus Jung

  49. Re: Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index

    Article • The Journal of Urology, March 2017, Wolters Kluwer Health

    Professor Klaus Jung

  50. Reply by Authors

    Article • The Journal of Urology, March 2017, Wolters Kluwer Health

    Professor Klaus Jung

  51. Does the Prostate Health Index Depend on Tumor Volume?—A Study on 196 Patients after Radical Prostatectomy

    Article • International Journal of Molecular Sciences, February 2017, MDPI AG

    Professor Klaus Jung

  52. Adipophilin as prognostic biomarker in clear cell renal cell carcinoma

    Article • Oncotarget, February 2017, Impact Journals, LLC

    Professor Klaus Jung

  53. Synthesis, Antiproliferative, and Antiangiogenic Activities of Benzochromene and Benzoquinoline Derivatives on Prostate Cancer in vitro

    Article • Letters in Drug Design & Discovery, February 2017, Bentham Science Publishers

    Professor Klaus Jung

  54. Antioxidant and antiproliferative potentials of methanol extract of Xylopia aethiopica (Dunal) A. Rich in PC-3 and LNCaP cells

    Article • Journal of Basic and Clinical Physiology and Pharmacology, January 2017, De Gruyter

    Professor Klaus Jung

  55. The translational potential of microRNAs as biofluid markers of urological tumours

    Article • Nature Reviews Urology, November 2016, Springer Science + Business Media

    Professor Klaus Jung

  56. Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index

    Article • The Journal of Urology, September 2016, Wolters Kluwer Health

    Professor Klaus Jung

  57. Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma

    Article • Scientific Reports, August 2016, Nature

    Professor Klaus Jung

  58. Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma

    Article • PLOS One, June 2016, PLOS

    Professor Klaus Jung

  59. Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p

    Article • PLOS One, February 2016, PLOS

    Professor Klaus Jung

  60. BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients

    Article • Oncotarget, January 2016, Impact Journals, LLC

    Professor Klaus Jung

  61. The way of prostate cancer diagnostics

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2016, De Gruyter

    Professor Klaus Jung

  62. Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients

    Article • Clinica Chimica Acta, January 2016, Elsevier

    Professor Klaus Jung

  63. New Insights Into the Mechanism of COP9 Signalosome–Cullin-RING Ubiquitin-Ligase Pathway Deregulation in Urological Cancers

    Article • January 2016, Elsevier

    Professor Klaus Jung

  64. Cytotoxic effects of octenidine mouth rinse on human fibroblasts and epithelial cells – an in vitro study

    Article • Drug and Chemical Toxicology, December 2015, Taylor & Francis

    Professor Klaus Jung

  65. Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer

    Article • Pathology, December 2015, Elsevier

    Professor Klaus Jung

  66. Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer

    Article • Oncotarget, November 2015, Impact Journals, LLC

    Professor Klaus Jung

  67. TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy

    Article • Virchows Archiv, November 2015, Springer Science + Business Media

    Professor Ben Vainer, Professor Klaus Jung

  68. The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer

    Article • Clinical Cancer Research, November 2015, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  69. Re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039

    Article • European Urology, November 2015, Elsevier

    Professor Klaus Jung

  70. Current biomarkers for diagnosing of prostate cancer

    Article • Future Oncology, October 2015, Future Medicine

    Professor Klaus Jung

  71. miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways

    Article • The Journal of Pathology, July 2015, Wiley

    Professor Klaus Jung

  72. Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas

    Article • Journal of Experimental & Clinical Cancer Research, June 2015, Springer Science + Business Media

    Professor Klaus Jung

  73. The percentage of prostate-specific antigen (PSA) isoform [-2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men

    Article • BJU International, May 2015, Wiley

    Professor Klaus Jung

  74. Antioxidant, antiangiogenic and antiproliferative activities of root methanol extract of Calliandra portoricensis in human prostate cancer cells

    Article • Journal of Integrative Medicine, May 2015, Elsevier

    Professor Klaus Jung

  75. Synthesis, crystal structure and effect of indeno[1,2-b]indole derivatives on prostate cancer in vitro. Potential effect against MMP-9

    Article • European Journal of Medicinal Chemistry, May 2015, Elsevier

    Professor Klaus Jung

  76. Neue Biomarker im Serum und im Urin zur Detektion des Prostatakarzinoms

    Article • Aktuelle Urologie, April 2015, Thieme Publishing Group

    Professor Klaus Jung

  77. Glutathione S-transferase-pi protein expression in prostate cancer-not always a useful diagnostic tool

    Article • Histopathology, April 2015, Wiley

    Professor Klaus Jung

  78. Urinary thiosulfate as failed prostate cancer biomarker – an exemplary multicenter re-evaluation study

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2015, De Gruyter

    Professor Klaus Jung

  79. Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2015, De Gruyter

    Professor Klaus Jung

  80. Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis

    Article • Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, December 2014, Elsevier

    Professor Klaus Jung

  81. Abstract 1415: Prostate cancer: An integrated evaluation of metabolomics, transcriptomics, and proteomics expression data

    Article • Cancer Research, October 2014, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  82. KDM5C Is Overexpressed in Prostate Cancer and Is a Prognostic Marker for Prostate-Specific Antigen-Relapse Following Radical Prostatectomy

    Article • American Journal Of Pathology, September 2014, Elsevier

    Professor Klaus Jung

  83. Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia

    Article • Virchows Archiv, August 2014, Springer Science + Business Media

    Professor Klaus Jung

  84. Prostate-specific antigen and other serum and urine markers in prostate cancer

    Article • Biochimica et Biophysica Acta (BBA) - Reviews on Cancer, August 2014, Elsevier

    Professor Klaus Jung

  85. Serum testosterone improves the accuracy of Prostate Health Index for the detection of prostate cancer

    Article • Clinical Biochemistry, July 2014, Elsevier

    Professor Klaus Jung

  86. miRNA panels as biomarkers for bladder cancer

    Article • Biomarkers in Medicine, June 2014, Future Medicine

    Professor Klaus Jung

  87. Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies

    Article • Critical Reviews in Clinical Laboratory Sciences, May 2014, Taylor & Francis

    Professor Klaus Jung

  88. Nucleic acid-based tissue biomarkers of urologic malignancies

    Article • Critical Reviews in Clinical Laboratory Sciences, May 2014, Taylor & Francis

    Professor Klaus Jung

  89. Risk prediction models for biochemical recurrence after radical prostatectomy using prostate-specific antigen and Gleason score

    Article • Asian Journal of Andrology, January 2014, Medknow

    Professor Klaus Jung

  90. The Antiapoptotic Function of miR-96 in Prostate Cancer by Inhibition of FOXO1

    Article • PLOS One, November 2013, PLOS

    Professor Klaus Jung

  91. miRNA Profiling Identifies Candidate miRNAs for Bladder Cancer Diagnosis and Clinical Outcome

    Article • Journal of Molecular Diagnostics, September 2013, Elsevier

    Professor Klaus Jung

  92. MicroRNA Signature Helps Distinguish Early from Late Biochemical Failure in Prostate Cancer

    Article • Clinical Chemistry, August 2013, AACC

    Professor Klaus Jung

  93. Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer

    Article • Oncology Reports, July 2013, Spandidos Publications

    Professor Klaus Jung

  94. Second primary malignancies in head and neck cancer patients

    Article • Strahlentherapie und Onkologie, July 2013, Springer Science + Business Media

    Professor Klaus Jung

  95. Deregulation of the COP9 signalosome–cullin-RING ubiquitin-ligase pathway: Mechanisms and roles in urological cancers

    Article • The International Journal of Biochemistry & Cell Biology, July 2013, Elsevier

    Professor Klaus Jung

  96. Pitfalls in the determination of circulating matrix metalloproteinases and their inhibitors by disregarding fundamental laboratory principles

    Article • American Heart Journal, June 2013, Elsevier

    Professor Klaus Jung

  97. Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma

    Article • International Journal of Cancer, June 2013, Wiley

    Professor Klaus Jung

  98. A New Algorithm for Integrated Analysis of miRNA-mRNA Interactions Based on Individual Classification Reveals Insights into Bladder Cancer

    Article • PLOS One, May 2013, PLOS

    Professor Klaus Jung

  99. Comparison of p40 (ΔNp63) and p63 expression in prostate tissues - which one is the superior diagnostic marker for basal cells?

    Article • Histopathology, May 2013, Wiley

    Professor Klaus Jung

  100. Use of microRNA signature to distinguish early from late biochemical failure in prostate cancer.

    Article • Journal of Clinical Oncology, February 2013, American Society of Clinical Oncology (ASCO)

    Professor Klaus Jung

  101. Artificial neural networks and prostate cancer—tools for diagnosis and management

    Article • Nature Reviews Urology, February 2013, Springer Science + Business Media

    Professor Klaus Jung

  102. Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy

    Article • Clinica Chimica Acta, February 2013, Elsevier

    Professor Klaus Jung

  103. MicroRNAs as New Diagnostic and Prognostic Biomarkers in Urological Tumors

    Article • Critical Reviews in Oncogenesis, January 2013, Begell House

    Professor Klaus Jung

  104. Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis

    Article • Journal of Translational Medicine, January 2013, Springer Science + Business Media

    Professor Klaus Jung

  105. Thiosulfate in urine: new hope or new failure of a biomarker for prostate cancer?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2013, De Gruyter

    Professor Klaus Jung

  106. Comparative Assessment of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG Gene Fusion with the Serum [-2]Proprostate-Specific Antigen-Based Prostate Health Index for Detection of Prostate Cancer

    Article • Clinical Chemistry, December 2012, AACC

    Professor Klaus Jung

  107. Multicenter Evaluation of [-2]Proprostate-Specific Antigen and the Prostate Health Index for Detecting Prostate Cancer

    Article • Clinical Chemistry, December 2012, AACC

    Professor Klaus Jung

  108. Value of Prostate Specific Antigen Density and Percent Free Prostate Specific Antigen for Prostate Cancer Prognosis

    Article • The Journal of Urology, December 2012, Wolters Kluwer Health

    Professor Klaus Jung

  109. N′-Formyl-2-(5-nitrothiophen-2-yl)benzothiazole-6-carbohydrazide as a potential anti-tumour agent for prostate cancer in experimental studies

    Article • Journal of Pharmacy and Pharmacology, November 2012, Wiley

    Professor Klaus Jung

  110. TMPRSS2-ERG Fusion Transcripts in Matched Urine and Needle Rinse Material after Biopsy for the Detection of Prostate Cancer: Really a Step Forward?

    Article • Clinical Chemistry, November 2012, AACC

    Professor Klaus Jung

  111. Selenoprotein P Status Correlates to Cancer-Specific Mortality in Renal Cancer Patients

    Article • PLOS One, October 2012, PLOS

    Professor Klaus Jung, Professor Lutz Schomburg

  112. Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated withSLC45A3-ERGgene rearrangement and an unfavorable clinical course

    Article • International Journal of Cancer, August 2012, Wiley

    Professor Klaus Jung

  113. Testicular radiation dose after multimodal curative therapy for locally advanced rectal cancer

    Article • Strahlentherapie und Onkologie, August 2012, Springer Science + Business Media

    Professor Klaus Jung

  114. Reference miRNAs for miRNAome Analysis of Urothelial Carcinomas

    Article • PLOS One, June 2012, PLOS

    Professor Klaus Jung

  115. A review of expression profiling of circulating microRNAs in men with prostate cancer

    Article • BJU International, May 2012, Wiley

    Professor Klaus Jung

  116. MiR-133b Targets Antiapoptotic Genes and Enhances Death Receptor-Induced Apoptosis

    Article • PLOS One, April 2012, PLOS

    Professor Klaus Jung

  117. Feedback networks between microRNAs and epigenetic modifications in urological tumors

    Article • Epigenetics, April 2012, Taylor & Francis

    Professor Klaus Jung

  118. The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer

    Article • Biological Chemistry, January 2012, De Gruyter

    Professor Klaus Jung

  119. Assay-dependent abnormalities in measurements of prostate-specific antigen in serum: an occasional occurrence, but of clinical significance

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2012, De Gruyter

    Professor Klaus Jung

  120. Identification of Metastamirs as Metastasis-associated MicroRNAs in Clear Cell Renal Cell Carcinomas

    Article • International Journal of Biological Sciences, January 2012, Ivyspring International Publisher

    Professor Klaus Jung

  121. Expression of endothelial factors in prostate cancer: a possible role of caveolin-1 for tumour progression

    Article • Oncology Reports, November 2011, Spandidos Publications

    Professor Klaus Jung

  122. RECK overexpression decreases invasive potential in prostate cancer cells

    Article • The Prostate, October 2011, Wiley

    Professor Klaus Jung

  123. Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases

    Article • Analytical Biochemistry, October 2011, Elsevier

    Professor Klaus Jung

  124. Avoiding Pitfalls in Applying Prediction Models, As Illustrated by the Example of Prostate Cancer Diagnosis

    Article • Clinical Chemistry, September 2011, AACC

    Professor Klaus Jung

  125. Feasibility of Flat Panel Angiographic CT after Intravenous Contrast Agent Application in the Postoperative Evaluation of Patients with Clipped Aneurysms

    Article • American Journal of Neuroradiology, August 2011, American Society of Neuroradiology (ASNR)

    Professor Klaus Jung

  126. Is there an optimal prostate-specific antigen threshold for prostate biopsy?

    Article • Expert Review of Anticancer Therapy, August 2011, Taylor & Francis

    Professor Klaus Jung

  127. Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma

    Article • BMC Cancer, July 2011, Springer Science + Business Media

    Professor Klaus Jung

  128. miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression

    Article • International Journal of Oncology, July 2011, Spandidos Publications

    Professor Klaus Jung

  129. Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo

    Article • Investigational New Drugs, July 2011, Springer Science + Business Media

    Professor Klaus Jung

  130. MicroRNAs as Regulators of Signal Transduction in Urological Tumors

    Article • Clinical Chemistry, June 2011, AACC

    Professor Klaus Jung

  131. Between-Method Differences in Prostate-Specific Antigen Assays Affect Prostate Cancer Risk Prediction by Nomograms

    Article • Clinical Chemistry, May 2011, AACC

    Professor Klaus Jung

  132. Importance of brain‑type fatty acid binding protein for cell-biological processes in human renal carcinoma cells

    Article • Oncology Reports, May 2011, Spandidos Publications

    Professor Klaus Jung

  133. Bone Turnover Markers as Predictors of Mortality Risk in Prostate Cancer Patients with Bone Metastases Following Treatment with Zoledronic Acid

    Article • European Urology, April 2011, Elsevier

    Professor Klaus Jung

  134. The Androgen-Regulated Calcium-Activated Nucleotidase 1 (CANT1) Is Commonly Overexpressed in Prostate Cancer and Is Tumor-Biologically Relevant in Vitro

    Article • American Journal Of Pathology, April 2011, Elsevier

    Professor Klaus Jung

  135. Sarcosine in Prostate Cancer Tissue is Not a Differential Metabolite for Prostate Cancer Aggressiveness and Biochemical Progression

    Article • The Journal of Urology, February 2011, Wolters Kluwer Health

    Professor Klaus Jung

  136. Decreased RECK and Increased EMMPRIN Expression in Urothelial Carcinoma of the Bladder Are Associated with Tumor Aggressiveness

    Article • Pathobiology, January 2011, Karger Publishers

    Professor Klaus Jung

  137. New 4-Maleamic Acid and 4-Maleamide Peptidyl Chalcones as Potential Multitarget Drugs for Human Prostate Cancer

    Article • Pharmaceutical Research, December 2010, Springer Science + Business Media

    Professor Klaus Jung

  138. Preanalytical Interferences Compromise the Clinical Validity of Matrix Metalloproteinase 1 as Marker of Colorectal Cancer

    Article • Annals of Surgical Oncology, December 2010, Springer Science + Business Media

    Professor Klaus Jung

  139. Metastamirs: a stepping stone towards improved cancer management

    Article • Nature Reviews Clinical Oncology, November 2010, Springer Science + Business Media

    Professor Klaus Jung

  140. Cell-free DNA in the blood as a solid tumor biomarker—A critical appraisal of the literature

    Article • Clinica Chimica Acta, November 2010, Elsevier

    Professor Klaus Jung

  141. Reply to Amitha K Hewavitharana’s Letter to the Editor re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine After Digital Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur ...

    Article • European Urology, October 2010, Elsevier

    Professor Klaus Jung

  142. Reply to Arun Sreekumar, Laila M. Poisson, Thekkelnaycke M. Rajendiran, et al.’s Letter to the Editor re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer De...

    Article • European Urology, September 2010, Elsevier

    Professor Klaus Jung

  143. Angiographic CT after Intravenous Contrast Agent Application: A Noninvasive Follow-Up Tool after Intracranial Angioplasty and Stenting

    Article • American Journal of Neuroradiology, July 2010, American Society of Neuroradiology (ASNR)

    Professor Klaus Jung

  144. Reply from Authors re: Jack A. Schalken. Is Urinary Sarcosine Useful to Identify Patients With Significant Prostate Cancer? The Trials and Tribulations of Biomarker Development. Eur Urol 2010;58:19–20

    Article • European Urology, July 2010, Elsevier

    Professor Klaus Jung

  145. Sarcosine in Urine after Digital Rectal Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours

    Article • European Urology, July 2010, Elsevier

    Professor Klaus Jung

  146. Periostin is up-regulated in high grade and high stage prostate cancer

    Article • BMC Cancer, June 2010, Springer Science + Business Media

    Professor Klaus Jung

  147. KLK15 is a prognostic marker for progression-free survival in patients with radical prostatectomy

    Article • International Journal of Cancer, May 2010, Wiley

    Professor Klaus Jung

  148. Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha-methylacyl-CoA racemase (AMACR) as prostatic cancer tissue marker

    Article • Histopathology, May 2010, Wiley

    Professor Klaus Jung

  149. Re: MicroRNA Regulation of Oncolytic Herpes Simplex Virus-1 for Selective Killing of Prostate Cancer Cells

    Article • European Urology, May 2010, Elsevier

    Professor Klaus Jung

  150. Robust MicroRNA Stability in Degraded RNA Preparations from Human Tissue and Cell Samples

    Article • Clinical Chemistry, April 2010, AACC

    Professor Klaus Jung

  151. Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors

    Article • Nature Reviews Urology, April 2010, Springer Science + Business Media

    Professor Klaus Jung

  152. Abstract 1772: Calcium activated nucleotidase 1 (CANT1) promotes progression of prostate carcinomas

    Article • Cancer Research, April 2010, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  153. Prostate Cancer Screening with Prostate-Specific Antigen Testing: More Answers or More Confusion?

    Article • Clinical Chemistry, March 2010, Oxford University Press (OUP)

    Professor Klaus Jung

  154. Measurement Conditions for Flow Cytometry Analyses of Cell Lines from Urological Carcinomas

    Article • Journal of Fluorescence, February 2010, Springer Science + Business Media

    Professor Klaus Jung

  155. Gene Promoter Methylation and Its Potential Relevance in Early Prostate Cancer Diagnosis

    Article • Pathobiology, January 2010, Karger Publishers

    Professor Klaus Jung

  156. Methodological weakness in using correlation coefficients for assessing the interchangeability of analyte data between samples collected under different sampling conditions – the example of matrix metalloproteinase 9 determined in serum and plasma samples

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2010, De Gruyter

    Professor Klaus Jung

  157. MicroRNAs and cancer: Current state and future perspectives in urologic oncology

    Article • Urologic Oncology Seminars and Original Investigations, January 2010, Elsevier

    Professor Klaus Jung

  158. Prostate Specific Antigen Density to Predict Prostate Cancer Upgrading in a Contemporary Radical Prostatectomy Series: A Single Center Experience

    Article • The Journal of Urology, January 2010, Wolters Kluwer Health

    Professor Klaus Jung

  159. Suitable reference genes for relative quantification of miRNA expression in prostate cancer

    Article • Experimental & Molecular Medicine, January 2010, Springer Science + Business Media

    Professor Klaus Jung

  160. Internal validation of an artificial neural network for prostate biopsy outcome

    Article • International Journal of Urology, November 2009, Wiley

    Professor Klaus Jung

  161. Consideration of preanalytical impact of blood sampling on measurement of matrix metalloproteinases and their inhibitors as precondition to evaluate their relationship to clinical data

    Article • Multiple Sclerosis Journal, November 2009, SAGE Publications

    Professor Klaus Jung

  162. Metabolic profiling reveals key metabolic features of renal cell carcinoma

    Article • Journal of Cellular and Molecular Medicine, October 2009, Wiley

    Professor Klaus Jung

  163. Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles

    Article • Journal of Translational Medicine, October 2009, Springer Science + Business Media

    Professor Klaus Jung

  164. Benign Prostatic Hyperplasia-associated Free Prostate-specific Antigen Improves Detection of Prostate Cancer in an Artificial Neural Network

    Article • Urology, October 2009, Elsevier

    Professor Klaus Jung

  165. Reduced Serum Selenoprotein P Concentrations in German Prostate Cancer Patients

    Article • Cancer Epidemiology Biomarkers & Prevention, August 2009, American Association for Cancer Research (AACR)

    Professor Klaus Jung, Professor Lutz Schomburg, Josef Köhrle

  166. Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer

    Article • BMC Cancer, August 2009, Springer Science + Business Media

    Professor Klaus Jung

  167. Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer?

    Article • BMC Cancer, July 2009, Springer Science + Business Media

    Professor Klaus Jung

  168. Divergent effects of taurolidine as potential anti-neoplastic agent: Inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo

    Article • Oncology Reports, July 2009, Spandidos Publications

    Professor Klaus Jung

  169. Neue Biomarker und Anwendung multivariater Modelle zur Detektion des Prostatakarzinoms

    Article • Aktuelle Urologie, July 2009, Thieme Publishing Group

    Professor Klaus Jung

  170. Mikro-RNA in der Uroonkologie

    Article • Der Urologe, June 2009, Springer Science + Business Media

    Professor Klaus Jung

  171. Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid

    Article • The Prostate, May 2009, Wiley

    Professor Klaus Jung

  172. 20–25% Lower Concentrations of Total and Free Prostate-Specific Antigen (PSA) after Calibration of PSA Assays to the WHO Reference Materials – Analysis of 1098 Patients in Four Centers

    Article • The International Journal of Biological Markers, April 2009, SAGE Publications

    Professor Klaus Jung

  173. Identification of Stanniocalcin 2 as Prognostic Marker in Renal Cell Carcinoma

    Article • European Urology, March 2009, Elsevier

    Professor Klaus Jung

  174. 170 20-25% LOWER PSA VALUES WITH PSA TEST STANDARDIZATION TO THE WHO REFERENCE MATERIAL: SUMMARY OF 4 STUDIES IN 1100 PATIENTS

    Article • European Urology Supplements, March 2009, Elsevier

    Professor Klaus Jung

  175. 296 AN AUTOMATED ASSAY FOR – 2PROPSA SIGNIFICANTLY IMPROVES PROSTATE CANCER (PCA) DETECTION IN ARTIFICIAL NEURAL NETWORK OR LOGISTIC REGRESSION MODELS AND ENHANCES DIFERENTIATION OF AGGRESSIVE PCA

    Article • European Urology Supplements, March 2009, Elsevier

    Professor Klaus Jung

  176. 1020 DIFFERENTIAL CLAUDIN-1 EXPRESSION PATTERN IN PAPILLARY AND CLEAR CELL RENAL CELL CARCINOMA IS ASSOCIATED WITH DIVERGENT TUMOUR BEHAVIOUR AND SURVIVAL

    Article • European Urology Supplements, March 2009, Elsevier

    Professor Klaus Jung

  177. 176 THE NEW AUTOMATED BPHA (BPSA) ASSAY IMPROVES DETECTION OF PROSTATE CANCER IN AN ARTIFICIAL NEURAL NETWORK

    Article • European Urology Supplements, March 2009, Elsevier

    Professor Klaus Jung

  178. MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy

    Article • Journal of Cellular and Molecular Medicine, February 2009, Wiley

    Professor Klaus Jung

  179. A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases

    Article • The Prostate, February 2009, Wiley

    Professor Klaus Jung

  180. Can nomograms be superior to other prediction tools?

    Article • BJU International, February 2009, Wiley

    Professor Klaus Jung

  181. Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients

    Article • European Journal of Cancer, February 2009, Elsevier

    Professor Klaus Jung

  182. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma

    Article • International Journal of Cancer, January 2009, Wiley

    Professor Klaus Jung

  183. 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials – analysis of 1098 patients in four centers

    Article • The International Journal of Biological Markers, January 2009, SAGE Publications

    Professor Klaus Jung

  184. By mistakes we learn: determination of matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 in serum yields doubtful results

    Article • Journal Of Clinical Periodontology, January 2009, Wiley

    Professor Klaus Jung

  185. Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2009, De Gruyter

    Professor Klaus Jung

  186. Synthesis of 7-chloroquinolinyl-4-

    Article • Scientia Pharmaceutica, January 2009, MDPI AG

    Professor Klaus Jung

  187. Germ Cell Tumors of the Gonads: A Selective Review Emphasizing Problems in Drug Resistance and Current Therapy Options

    Article • Oncology, December 2008, Karger Publishers

    Professor Klaus Jung

  188. Disease State, Age, Sex, and Post-Mortem Time-Dependent Expression of Proteins in AD vs. Control Frontal Cortex Brain Samples

    Article • Current Alzheimer Research, December 2008, Bentham Science Publishers

    Professor Klaus Jung

  189. Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer

    Article • BMC Cancer, December 2008, Springer Science + Business Media

    Professor Klaus Jung

  190. Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood

    Article • Clinical Biochemistry, December 2008, Elsevier

    Professor Klaus Jung

  191. Measurement of Matrix Metalloproteinases and Their Tissue Inhibitors in Serum Produces Doubtful Results

    Article • The Journal of Infectious Diseases, December 2008, Oxford University Press (OUP)

    Professor Klaus Jung

  192. GOLPH2 expression in renal cell cancer

    Article • BMC Urology, November 2008, Springer Science + Business Media

    Professor Klaus Jung

  193. By mistakes we learn: determination of matrix metalloproteinase‐8 and tissue inhibitor of matrix metalloproteinase‐1 in serum yields doubtful results

    Article • Journal Of Clinical Periodontology, November 2008, Wiley

    Professor Klaus Jung

  194. ADAM9 Expression is a Significant and Independent Prognostic Marker of PSA Relapse in Prostate Cancer

    Article • European Urology, November 2008, Elsevier

    Professor Klaus Jung

  195. Circulating Matrix Metalloproteinase-7: An Early or Metastatic Marker for Renal Cell Carcinoma?

    Article • Clinical Chemistry, November 2008, AACC

    Professor Klaus Jung

  196. Claudin-1 Protein Expression is a Prognostic Marker of Patient Survival in Renal Cell Carcinomas

    Article • Clinical Cancer Research, November 2008, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  197. Re: The Metabolites Citrate, Myo-Inositol, and Spermine Are Potential Age-Independent Markers of Prostate Cancer in Human Expressed Prostatic Secretions

    Article • European Urology, November 2008, Elsevier

    Professor Klaus Jung

  198. An artificial neural network for five different assay systems of prostate-specific antigen in prostate cancer diagnostics

    Article • BJU International, October 2008, Wiley

    Professor Klaus Jung

  199. Editorial Comment

    Article • The Journal of Urology, October 2008, Wolters Kluwer Health

    Professor Klaus Jung

  200. Re: Al-Azab R, Toi A, Lockwood G, et al. Prostate Volume Is Strongest Predictor of Cancer Diagnosis at Transrectal Ultrasound-Guided Prostate Biopsy with Prostate-Specific Antigen Values Between 2.0 and 9.0 ng/mL (Urology 69:103-107, 2007)

    Article • Urology, October 2008, Elsevier

    Professor Klaus Jung

  201. Reply

    Article • BJU International, October 2008, Wiley

    Professor Klaus Jung

  202. Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity

    Article • BMC Urology, September 2008, Springer Science + Business Media

    Professor Klaus Jung

  203. A strong note of caution in using matrix metalloproteinase-1 and its inhibitor, TIMP-1 in serum as biomarkers in systolic heart failure

    Article • Journal of Internal Medicine, September 2008, Wiley

    Professor Klaus Jung

  204. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics

    Article • British Journal of Cancer, September 2008, Springer Science + Business Media

    Professor Klaus Jung

  205. Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma

    Article • Cancer Letters, September 2008, Elsevier

    Professor Klaus Jung

  206. Blood sampling affects circulating TIMP-1 concentration, a useful biomarker in estimating liver fibrosis stages

    Article • Hepatology, August 2008, Wiley

    Professor Klaus Jung

  207. CD146 protein in prostate cancer: revisited with two different antibodies

    Article • Pathology, August 2008, Elsevier

    Professor Klaus Jung

  208. Editorial Comment

    Article • The Journal of Urology, August 2008, Wolters Kluwer Health

    Professor Klaus Jung

  209. Editorial Comment on: Diagnostic Value of Free Prostate-Specific Antigen among Men with a Prostate-Specific Antigen Level of <3.0μg per Liter

    Article • European Urology, August 2008, Elsevier

    Professor Klaus Jung

  210. Proteomic Analysis of Conditioned Media from the PC3, LNCaP, and 22Rv1 Prostate Cancer Cell Lines: Discovery and Validation of Candidate Prostate Cancer Biomarkers

    Article • Journal of Proteome Research, August 2008, American Chemical Society (ACS)

    Professor Klaus Jung

  211. Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy

    Article • British Journal of Cancer, July 2008, Springer Science + Business Media

    Professor Klaus Jung

  212. ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression

    Article • BMC Cancer, June 2008, Springer Science + Business Media

    Professor Klaus Jung

  213. Plasma matrix metalloproteinase-7 as a metastatic marker and survival predictor in patients with renal cell carcinomas

    Article • Cancer Science, June 2008, Wiley

    Professor Klaus Jung

  214. Matrix metalloproteinases do not properly work as peripheral blood biomarkers without taking into account the preanalytical impact of blood sampling

    Article • European Journal of Cardio-Thoracic Surgery, May 2008, Oxford University Press (OUP)

    Professor Klaus Jung

  215. Re: Application of Artificial Intelligence to the Management of Urological Cancer

    Article • The Journal of Urology, May 2008, Wolters Kluwer Health

    Professor Klaus Jung

  216. Blood sampling and the measurement of circulating matrix metalloproteinase-8

    Article • Clinica Chimica Acta, April 2008, Elsevier

    Professor Klaus Jung

  217. European and US publications in the 50 highest ranking pathology journals from 2000 to 2006

    Article • Journal of Clinical Pathology, April 2008, BMJ

    Professor Klaus Jung

  218. Impact of Blood Sampling on the Circulating Matrix Metalloproteinases 1, 2, 3, 7, 8, and 9

    Article • Clinical Chemistry, April 2008, AACC

    Professor Klaus Jung

  219. Matrix Metalloproteinase-8 and Tissue Inhibitor of Metalloproteinase-1 in Serum Do Not Reflect the Analytes Circulating in Blood

    Article • Arteriosclerosis Thrombosis and Vascular Biology, March 2008, Wolters Kluwer Health

    Professor Klaus Jung

  220. AN ARTIFICIAL NEURAL NETWORK FOR FIVE DIFFERENT PSAASSAYS IN PROSTATE CANCER DIAGNOSTICS

    Article • European Urology Supplements, March 2008, Elsevier

    Professor Klaus Jung

  221. COMPARISON OF THE “GOLD” STANDARD ACCESS ® PSA (HYBRITECH) ASSAY WITH THE NEW BECKMAN COULTER WHO- STANDARDIZED CALIBRATED ACCESS ® PSA ASSAYS

    Article • European Urology Supplements, March 2008, Elsevier

    Professor Klaus Jung

  222. THE MATRIX-METALLOPROTEINASE INHIBITOR RECK AFFECTS PROSTATE CANCER PROGRESSION

    Article • European Urology Supplements, March 2008, Elsevier

    Professor Klaus Jung

  223. Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression

    Article • International Journal of Oncology, February 2008, Spandidos Publications

    Professor Klaus Jung

  224. Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

    Article • British Journal of Cancer, January 2008, Springer Science + Business Media

    Professor Klaus Jung

  225. High Expression of KLK14 in Prostatic Adenocarcinoma Is Associated with Elevated Risk of Prostate-Specific Antigen Relapse

    Article • Tumor Biology, January 2008, Springer Science + Business Media

    Professor Klaus Jung

  226. Serum samples are inappropriate for use in measuring circulating matrix metalloproteinases: Comment on the article by Young-Min et al

    Article • Arthritis & Rheumatism, January 2008, Wiley

    Professor Klaus Jung

  227. Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2008, De Gruyter

    Professor Klaus Jung

  228. Two-Dimensional Electrophoresis in Prostate Cancer Research and Diagnostics

    Article • Laboratory Medicine, December 2007, Oxford University Press (OUP)

    Professor Klaus Jung

  229. Reply to C.J. Shukla, Dylan Edwards and Krishna K. Sethia’s Letter to the Editor re: Anja Rabien, Mick Burkhardt, Monika Jung, Florian Fritzsche, Martin Ringsdorf, Hanka Schicktanz, Stefan A. Loening, Glen Kristiansen and Klaus Jung. Decreased RECK Exp...

    Article • European Urology, November 2007, Elsevier

    Professor Klaus Jung

  230. Serial Markers of Bone Turnover in Men with Metastatic Prostate Cancer Treated with Zoledronic Acid for Detection of Bone Metastases Progression

    Article • European Urology, November 2007, Elsevier

    Professor Klaus Jung

  231. A Bibliometric Evaluation of Publications in Urological Journals among European Union Countries between 2000–2005

    Article • European Urology, October 2007, Elsevier

    Professor Klaus Jung

  232. Comparison of Two Different Artificial Neural Networks for Prostate Biopsy Indication in Two Different Patient Populations

    Article • Urology, September 2007, Elsevier

    Professor Klaus Jung

  233. PSA and other tissue kallikreins for prostate cancer detection

    Article • European Journal of Cancer, September 2007, Elsevier

    Professor Klaus Jung

  234. Neue Serummarker des Prostatakarzinoms und ihr Einsatz in artifiziellen neuronalen Netzwerken (ANN)

    Article • Der Urologe, July 2007, Springer Science + Business Media

    Professor Klaus Jung

  235. Neue Serummarker zur Diagnostik von Knochenmetastasen beim Prostatakarzinom

    Article • Der Urologe, July 2007, Springer Science + Business Media

    Professor Klaus Jung

  236. Quantifizierung von Genexpressionen beim Prostatakarzinom

    Article • Der Urologe, July 2007, Springer Science + Business Media

    Professor Klaus Jung

  237. Der Tumorsuppressor RECK im Prostatakarzinom

    Article • Der Urologe, July 2007, Springer Science + Business Media

    Professor Klaus Jung

  238. Humane Kallikreine als Tumormarker

    Article • Der Urologe, July 2007, Springer Science + Business Media

    Professor Klaus Jung

  239. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies

    Article • BJU International, June 2007, Wiley

    Professor Klaus Jung

  240. Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma

    Article • Journal of Cancer Research and Clinical Oncology, May 2007, Springer Science + Business Media

    Professor Klaus Jung

  241. Decreased RECK Expression Indicating Proteolytic Imbalance in Prostate Cancer is Associated with Higher Tumor Aggressiveness and Risk of Prostate-Specific Antigen Relapse after Radical Prostatectomy

    Article • European Urology, May 2007, Elsevier

    Professor Klaus Jung

  242. Discovery and Validation of 3 Novel DNA Methylation Markers of Prostate Cancer Prognosis

    Article • The Journal of Urology, May 2007, Wolters Kluwer Health

    Professor Klaus Jung

  243. Re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial Biopsy Outcome Prediction—Head-to-Head Comparison of a Logistic Regression-Based Nomogram versus Ar...

    Article • European Urology, May 2007, Elsevier

    Professor Klaus Jung

  244. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer

    Article • Cancer Letters, April 2007, Elsevier

    Professor Klaus Jung

  245. Free PSA forms in prostatic tissue and sera of prostate cancer patients: Analysis by 2-DE and western blotting of immunopurified samples

    Article • Clinical Biochemistry, March 2007, Elsevier

    Professor Klaus Jung

  246. Re: A Molecular Correlate to the Gleason Grading System for Prostate Adenocarcinoma

    Article • European Urology, March 2007, Elsevier

    Professor Klaus Jung

  247. Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2–10 ng/ml in 4,480 men

    Article • World Journal of Urology, February 2007, Springer Science + Business Media

    Professor Klaus Jung

  248. Electrophoretic Subforms of Free Prostate-Specific Antigen in Serum as Promising Diagnostic Tool in Prostate Cancer Diagnostics

    Article • Urology, February 2007, Elsevier

    Professor Klaus Jung

  249. In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR

    Article • BMC Molecular Biology, January 2007, Springer Science + Business Media

    Professor Klaus Jung

  250. Morbidity and quality of life during thermotherapy using magnetic nanoparticles in locally recurrent prostate cancer: Results of a prospective phase I trial

    Article • International Journal of Hyperthermia, January 2007, Taylor & Francis

    Professor Klaus Jung

  251. Overexpression of cyclooxygenase-2 in human prostate carcinoma and prostatic intraepithelial neoplasia-association with increased expression of polo-like kinase-1

    Article • The Prostate, January 2007, Wiley

    Professor Klaus Jung

  252. Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer

    Article • The Prostate, January 2007, Wiley

    Professor Klaus Jung

  253. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma

    Article • Clinical Biochemistry, January 2007, Elsevier

    Professor Klaus Jung

  254. S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk—A re-evaluation study

    Article • The Prostate, January 2007, Wiley

    Professor Klaus Jung

  255. Complications, Urinary Continence, and Oncologic Outcome of 1000 Laparoscopic Transperitoneal Radical Prostatectomies—Experience at the Charité Hospital Berlin, Campus Mitte

    Article • European Urology, December 2006, Elsevier

    Professor Klaus Jung

  256. ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis

    Article • Virchows Archiv, November 2006, Springer Science + Business Media

    Professor Klaus Jung

  257. A (-5, -7) ProPSA Based Artificial Neural Network to Detect Prostate Cancer

    Article • European Urology, November 2006, Elsevier

    Professor Klaus Jung

  258. Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases

    Article • Clinica Chimica Acta, November 2006, Elsevier

    Professor Klaus Jung

  259. Diagnostic and Prognostic Validity of Serum Bone Turnover Markers in Metastatic Renal Cell Carcinoma

    Article • The Journal of Urology, October 2006, Wolters Kluwer Health

    Professor Klaus Jung

  260. Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder

    Article • BMC Urology, August 2006, Springer Science + Business Media

    Professor Klaus Jung

  261. Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model

    Article • Cancer Chemotherapy and Pharmacology, June 2006, Springer Science + Business Media

    Professor Klaus Jung

  262. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network

    Article • Biological Chemistry, June 2006, De Gruyter

    Dr Terukazu Nakamura, Professor Klaus Jung

  263. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network

    Article • The Prostate, May 2006, Wiley

    Dr Terukazu Nakamura, Professor Klaus Jung

  264. Identification and Validation of Suitable Endogenous Reference Genes for Gene Expression Studies of Human Bladder Cancer

    Article • The Journal of Urology, May 2006, Wolters Kluwer Health

    Professor Klaus Jung

  265. Impact of Blood Sampling on Circulating Tissue Inhibitors of Metalloproteinases

    Article • Clinical Cancer Research, April 2006, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  266. New Insights Into the Diagnostic Accuracy of Complexed and Total Prostate Specific Antigen Using Discordance Analysis Characteristics

    Article • The Journal of Urology, April 2006, Wolters Kluwer Health

    Professor Klaus Jung

  267. A Renewed Approach to the Nonparametric Analysis of Replicated Microarray Experiments

    Article • Biometrical Journal, April 2006, Wiley

    Professor Klaus Jung

  268. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer

    Article • International Journal of Urology, March 2006, Wiley

    Dr Terukazu Nakamura, Professor Klaus Jung

  269. Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status

    Article • British Journal of Cancer, January 2006, Springer Science + Business Media

    Professor Klaus Jung

  270. Interchangeability of Measurements of Total and Free Prostate-Specific Antigen in Serum with 5 Frequently Used Assay Combinations: An Update

    Article • Clinical Chemistry, January 2006, AACC

    Professor Klaus Jung

  271. Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis

    Article • Clinical Cancer Research, January 2006, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  272. Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2006, De Gruyter

    Professor Klaus Jung

  273. Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer

    Article • The Prostate, January 2006, Wiley

    Professor Klaus Jung

  274. Loss of the tissue-specific proapoptotic BH3-only protein Nbk/Bik is a unifying feature of renal cell carcinoma

    Article • Cell Death and Differentiation, December 2005, Nature

    Professor Klaus Jung

  275. A MULTICENTER CLINICAL TRIAL ON THE USE OF (–5, –7) PRO PROSTATE SPECIFIC ANTIGEN

    Article • The Journal of Urology, December 2005, Wolters Kluwer Health

    Professor Klaus Jung

  276. Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of Prostate-Specific Antigen (PSA) Isoforms for the Detection of Prostate Cancer in Men with a PSA Level of 2–10ng/ml: Systematic Review and Meta-Analysis. Eur Urol 2005;48:386–99

    Article • European Urology, December 2005, Elsevier

    Professor Klaus Jung

  277. Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization?

    Article • Journal of Molecular Medicine, October 2005, Springer Science + Business Media

    Professor Klaus Jung

  278. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection

    Article • BJU International, September 2005, Wiley

    Professor Klaus Jung

  279. Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats

    Article • Anti-Cancer Drugs, September 2005, Wolters Kluwer Health

    Professor Klaus Jung

  280. Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma

    Article • Oncology Reports, September 2005, Spandidos Publications

    Professor Klaus Jung

  281. Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model

    Article • The Prostate, August 2005, Wiley

    Professor Klaus Jung

  282. Pre-analytical conditions for the assessment of circulating MMP-9 and TIMP-1: consideration of pitfalls

    Article • European Respiratory Journal, August 2005, European Respiratory Society (ERS)

    Professor Klaus Jung

  283. Consideration of Important Preanalytical Conditions for the Assessment of Circulating Matrix Metalloproteinase-9

    Article • American Review of Respiratory Disease, July 2005, American Thoracic Society

    Professor Klaus Jung

  284. Artificial neural networks: has the time come for their use in prostate cancer patients?

    Article • Nature Clinical Practice Urology, June 2005, Springer Science + Business Media

    Professor Klaus Jung

  285. Misinterpretation of quantitative RT-PCR results: A comment on the article by Ohashi et al. “RNA degradation in human breast tissue after surgical removal: a time course study”, Exp. Mol. Pathol. 77 (2004) 98–103

    Article • Experimental and Molecular Pathology, June 2005, Elsevier

    Professor Klaus Jung

  286. Serum or plasma: What kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors?

    Article • Journal of Neuroimmunology, May 2005, Elsevier

    Professor Klaus Jung

  287. Consideration of Preanalytical Conditions to Use Circulating Matrix Metalloproteinases as Diagnostic Markers

    Article • Transplantation, March 2005, Wolters Kluwer Health

    Professor Klaus Jung

  288. Discordance Analysis Characteristics as a New Method to Compare the Diagnostic Accuracy of Tests: Example of Complexed Versus Total Prostate-Specific Antigen

    Article • Clinical Chemistry, March 2005, AACC

    Professor Klaus Jung

  289. Intron Retention: A Common Splicing Event within the Human Kallikrein Gene Family

    Article • Clinical Chemistry, March 2005, AACC

    Professor Klaus Jung

  290. Is NF-κB predictive of biochemical recurrence in positive-margin prostate cancer?

    Article • Nature Clinical Practice Urology, March 2005, Springer Science + Business Media

    Professor Klaus Jung

  291. The Clinical Chemist

    Article • Clinical Chemistry, February 2005, AACC

    Professor Klaus Jung

  292. Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes

    Article • International Journal of Cancer, January 2005, Wiley

    Professor Klaus Jung

  293. Careful attention to blood sampling as a preanalytical determinant of circulating matrix metalloproteinase 9 to avoid misinterpretations: Comment on the article by Ainiala et al

    Article • Arthritis & Rheumatism, January 2005, Wiley

    Professor Klaus Jung

  294. Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: A re-evaluation

    Article • The Prostate, January 2005, Wiley

    Professor Klaus Jung

  295. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL

    Article • Cancer, January 2005, Wiley

    Professor Klaus Jung

  296. Analysis of Subforms of Free Prostate-Specific Antigen in Serum by Two-Dimensional Gel Electrophoresis: Potential to Improve Diagnosis of Prostate Cancer

    Article • Clinical Chemistry, December 2004, AACC

    Professor Klaus Jung

  297. THE MEMBRANE PROTEASES ADAMS AND HEPSIN ARE DIFFERENTIALLY EXPRESSED IN RENAL CELL CARCINOMA. ARE THEY POTENTIAL TUMOR MARKERS?

    Article • The Journal of Urology, December 2004, Wolters Kluwer Health

    Professor Klaus Jung

  298. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder

    Article • Oncology Reports, October 2004, Spandidos Publications

    Professor Klaus Jung

  299. Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8?16

    Article • European Urology, August 2004, Elsevier

    Professor Klaus Jung

  300. Evaluation of Magnetic Fluid Hyperthermia in a Standard Rat Model of Prostate Cancer

    Article • Journal of Endourology, June 2004, Mary Ann Liebert Inc

    Professor Klaus Jung

  301. Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder

    Article • Urology, June 2004, Elsevier

    Professor Klaus Jung

  302. Repeating the measurement of prostate-specific antigen in symptomatic men can avoid unnecessary prostatic biopsy

    Article • BJU International, June 2004, Wiley

    Professor Klaus Jung

  303. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications

    Article • International Journal of Cancer, May 2004, Wiley

    Professor Klaus Jung

  304. Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate‐specific antigen levels ≤ 10 ng/ml

    Article • Cancer, March 2004, Wiley

    Professor Klaus Jung

  305. Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer

    Article • Cancer Letters, March 2004, Elsevier

    Professor Klaus Jung

  306. Serum Macrophage Migration Inhibitory Factor Is Not Elevated in Patients with Prostate Cancer

    Article • Cancer Epidemiology Biomarkers & Prevention, February 2004, American Association for Cancer Research (AACR)

    Professor Klaus Jung

  307. Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome

    Article • Oncology Reports, February 2004, Spandidos Publications

    Professor Klaus Jung

  308. Hepsin is Highly Over Expressed in and a New Candidate for a Prognostic Indicator in Prostate Cancer

    Article • The Journal of Urology, January 2004, Elsevier

    Dr Terukazu Nakamura, Professor Klaus Jung

  309. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy

    Article • The Prostate, January 2004, Wiley

    Professor Klaus Jung

  310. Differential Expression of a Human Kallikrein 5 (KLK5) Splice Variant in Ovarian and Prostate Cancer

    Article • Tumor Biology, January 2004, Springer Science + Business Media

    Professor Klaus Jung

  311. Molecular Cloning of a New Gene Which Is Differentially Expressed in Breast and Prostate Cancers

    Article • Tumor Biology, January 2004, Springer Science + Business Media

    Professor Klaus Jung

  312. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades

    Article • The Prostate, January 2004, Wiley

    Professor Klaus Jung

  313. Author reply

    Article • Cancer, January 2004, Wiley

    Professor Klaus Jung

  314. The Kallikrein Gene 5 Splice Variant 2 Is a New Biomarker for Breast and Ovarian Cancer

    Article • Tumor Biology, January 2004, Springer Science + Business Media

    Professor Klaus Jung

  315. Serum Osteoprotegerin and Receptor Activator of Nuclear Factor-κ B Ligand as Indicators of Disturbed Osteoclastogenesis in Patients With Prostate Cancer

    Article • The Journal of Urology, December 2003, Wolters Kluwer Health

    Professor Klaus Jung

  316. Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma

    Article • Urological Research, December 2003, Springer Science + Business Media

    Professor Klaus Jung

  317. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer

    Article • The Prostate, November 2003, Wiley

    Professor Klaus Jung

  318. A Multicenter Clinical Trial On the Use of Complexed Prostate Specific Antigen in Low Prostate Specific Antigen Concentrations

    Article • The Journal of Urology, October 2003, Wolters Kluwer Health

    Professor Klaus Jung

  319. Nutzung von artifiziellen neuronalen Netzwerken zur Risikoabsch�tzung eines Prostatakarzinoms

    Article • Der Urologe, September 2003, Springer Science + Business Media

    Professor Klaus Jung

  320. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues

    Article • The Prostate, June 2003, Wiley

    Professor Klaus Jung

  321. Changes in Concentration of DNA in Serum and Plasma during Storage of Blood Samples

    Article • Clinical Chemistry, June 2003, AACC

    Professor Klaus Jung

  322. Determination of Non- 1-Antichymotrypsin-complexed Prostate-specific Antigen as an Indirect Measurement of Free Prostate-specific Antigen: Analytical Performance and Diagnostic Accuracy

    Article • Clinical Chemistry, June 2003, AACC

    Professor Klaus Jung

  323. Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues

    Article • Urology, May 2003, Elsevier

    Dr Terukazu Nakamura, Professor Klaus Jung

  324. Quantitative analysis of macrophage inhibitory cytokine-1 (MIC-1) gene expression in human prostatic tissues

    Article • British Journal of Cancer, April 2003, Springer Science + Business Media

    Professor Klaus Jung

  325. mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue

    Article • The Prostate, March 2003, Wiley

    Professor Klaus Jung

  326. Comparison of Eight Computer Programs for Receiver-Operating Characteristic Analysis

    Article • Clinical Chemistry, March 2003, AACC

    Tania Schink, Professor Klaus Jung

  327. Quantitative Analysis of Kallikrein 15 Gene Expression in Prostate Tissue

    Article • The Journal of Urology, January 2003, Elsevier

    Dr Terukazu Nakamura, Professor Klaus Jung

  328. Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats

    Article • The Prostate, December 2002, Wiley

    Professor Klaus Jung

  329. Tissue inhibitors of metalloproteinases 1 and 2 in human seminal plasma and their association with spermatozoa

    Article • International Journal of Andrology, December 2002, Wiley

    Professor Klaus Jung

  330. Quantitative differences in matrix metalloproteinase (MMP)-2, but not in MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 or TIMP-2, in seminal plasma of normozoospermic and azoospermic patients

    Article • Human Reproduction, November 2002, Oxford University Press (OUP)

    Professor Klaus Jung

  331. Different mRNA and Protein Expression of Matrix Metalloproteinases 2 and 9 and Tissue Inhibitor of Metalloproteinases 1 in Benign and Malignant Prostate Tissue

    Article • European Urology, October 2002, Elsevier

    Professor Klaus Jung

  332. Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues

    Article • Urology, October 2002, Elsevier

    Professor Klaus Jung

  333. Circulating gelatinase B (MMP-9)—the impact of the preanalytical step of blood collectionRE: Zymographic analysis of circulating and tissue forms of colon carcinoma gelatinase A (MMP-2) and B (MMP-9) separated by mono- and two-dimensional electrophores...

    Article • Matrix Biology, August 2002, Elsevier

    Professor Klaus Jung

  334. An artificial neural network considerably improves the diagnostic power of percent free prostate-specific antigen in prostate cancer diagnosis: Results of a 5-year investigation

    Article • International Journal of Cancer, April 2002, Wiley

    Professor Klaus Jung

  335. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues

    Article • The Prostate, April 2002, Wiley

    Professor Klaus Jung

  336. Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers

    Article • The Prostate, March 2002, Wiley

    Professor Klaus Jung

  337. The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model

    Article • Oncogene, March 2002, Springer Science + Business Media

    Professor Klaus Jung

  338. Cathepsins B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder

    Article • Urology, February 2002, Elsevier

    Professor Klaus Jung

  339. LETTERS TO THE EDITOR

    Article • Respiratory Medicine, February 2002, Elsevier

    Professor Klaus Jung

  340. INCREASED PRODUCTION OF MATRIX METALLOPROTEINASE-2 IN ALVEOLAR MACROPHAGES AND REGULATION BY INTERLEUKIN-10 IN PATIENTS WITH ACUTE PULMONARY SARCOIDOSIS

    Article • Experimental Lung Research, January 2002, Taylor & Francis

    Professor Klaus Jung

  341. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer

    Article • Urology, January 2002, Elsevier

    Professor Klaus Jung

  342. Article • APOPTOSIS, January 2002, Springer Science + Business Media

    Professor Klaus Jung

  343. RE: A PROSPECTIVE STUDY TO EVALUATE THE ROLE OF COMPLEXED PROSTATE SPECIFIC ANTIGEN AND FREE/TOTAL PROSTATE SPECIFIC ANTIGEN RATIO FOR THE DIAGNOSIS OF PROSTATE CANCER

    Article • The Journal of Urology, January 2002, Wolters Kluwer Health

    Professor Klaus Jung

  344. Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines

    Article • The Prostate, December 2001, Wiley

    Professor Klaus Jung

  345. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood

    Article • Clinica Chimica Acta, December 2001, Elsevier

    Professor Klaus Jung

  346. Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer

    Article • British Journal of Cancer, July 2001, Springer Science + Business Media

    Professor Klaus Jung

  347. Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue

    Article • British Journal of Cancer, July 2001, Springer Science + Business Media

    Professor Klaus Jung

  348. Identification and Characterization of a Novel Human Testis-Specific Kinase Substrate Gene Which Is Downregulated in Testicular Tumors

    Article • Biochemical and Biophysical Research Communications, July 2001, Elsevier

    Professor Klaus Jung

  349. Molecular Cloning of a Novel Human Acid Phosphatase Gene (ACPT) That Is Highly Expressed in the Testis

    Article • Genomics, June 2001, Elsevier

    Professor Klaus Jung

  350. Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma

    Article • Urology, April 2001, Elsevier

    Professor Klaus Jung

  351. Dimethyl Sulfoxide as Additive in Ready-to-Use Reaction Mixtures for Real-Time Polymerase Chain Reaction Analysis with SYBR Green I Dye

    Article • Analytical Biochemistry, February 2001, Elsevier

    Professor Klaus Jung

  352. Rapid Detection of Macroprolactin in tHe Form of Prolactin-Immunoglobulin G Complexes by Immunoprecipitation with Anti-human IgG-Agarose

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2001, De Gruyter

    Professor Klaus Jung

  353. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis

    Article • The Prostate, January 2001, Wiley

    Professor Klaus Jung

  354. Comparison of the Clinical Validity of Free Prostate–Specific Antigen, Alpha–1 Antichymotrypsin–Bound Prostate–Specific Antigen and Complexed Prostate–Specific Antigen in Prostate Cancer Diagnosis

    Article • European Urology, January 2001, Elsevier

    Professor Klaus Jung

  355. Molecular forms of prostate-specific antigen in serum with concentrations of total prostate-specific antigen <4 ?g/L: Are they useful tools for early detection and screening of prostate cancer?

    Article • International Journal of Cancer, January 2001, Wiley

    Professor Klaus Jung

  356. Receiver-operating characteristic as a tool for evaluating the diagnostic performance of prostate-specific antigen and its molecular forms?What has to be considered?

    Article • The Prostate, January 2001, Wiley

    Professor Klaus Jung

  357. Tumor M2 Pyruvate Kinase in Plasma of Patients with Urological Tumors

    Article • Tumor Biology, January 2001, Springer Science + Business Media

    Professor Klaus Jung

  358. Tumor-M2-Pyruvatkinase beim Nierenzellkarzinom

    Article • Der Urologe, November 2000, Springer Science + Business Media

    Professor Klaus Jung

  359. RE: COMPLEXED PROSTATE SPECIFIC ANTIGEN PROVIDES SIGNIFICANT ENHANCEMENT OF SPECIFICITY COMPARED WITH TOTAL PROSTATE SPECIFIC ANTIGEN FOR DETECTING PROSTATE CANCER

    Article • The Journal of Urology, November 2000, Wolters Kluwer Health

    Professor Klaus Jung

  360. Molecular Cloning of the HumanKallikrein 15Gene (KLK15)

    Article • Journal of Biological Chemistry, September 2000, American Society for Biochemistry & Molecular Biology (ASBMB)

    Professor Klaus Jung

  361. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue

    Article • Urology, September 2000, Elsevier

    Professor Klaus Jung

  362. Molekulare Formen des prostataspezifischen Antigens und des humanen Kallikreins 2 als mögliche Indikatoren in der Prostatakarzinomdiagnostik

    Article • Der Urologe, July 2000, Springer Science + Business Media

    Professor Klaus Jung

  363. Laser-induced hyperthermia in rat prostate cancer: role of site of tumor implantation

    Article • Urology, July 2000, Elsevier

    Professor Klaus Jung

  364. Urinary markers of malignancy

    Article • Clinica Chimica Acta, July 2000, Elsevier

    Professor Klaus Jung

  365. Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model

    Article • The Prostate, May 2000, Wiley

    Professor Klaus Jung

  366. ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation

    Article • Urology, April 2000, Elsevier

    Professor Klaus Jung

  367. Relationship between semen quality and the seminal plasma components carnitine, alpha-glucosidase, fructose, citrate and granulocyte elastase in infertile men compared with a normal population

    Article • Human Reproduction, April 2000, Oxford University Press (OUP)

    Professor Klaus Jung

  368. Matrix-metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma

    Article • International Journal of Cancer, March 2000, Wiley

    Professor Klaus Jung

  369. Elimination of Serum Complexed Prostate-Specific Antigen after Radical Retropubic Prostatectomy

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2000, De Gruyter

    Professor Klaus Jung

  370. Different Stability of Free and Complexed Prostate-Specific Antigen in Serum in Relation to Specimen Handling and Storage Conditions

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 2000, De Gruyter

    Professor Klaus Jung

  371. Different effects of cyclosporine and tacrolimus on the activation of mesangial metalloproteinases and their inhibitors

    Article • Transplantation Proceedings, November 1999, Elsevier

    Professor Klaus Jung

  372. RE: FREE AND COMPLEXED PROSTATE SPECIFIC ANTIGEN IN THE DIFFERENTIATION OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER

    Article • The Journal of Urology, August 1999, Wolters Kluwer Health

    Professor Klaus Jung

  373. Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate

    Article • Pediatric Nephrology, July 1999, Springer Science + Business Media

    Professor Klaus Jung, Professor Guido Filler

  374. Analytical Aspects regarding the Measurement of Metalloproteinases

    Article • Annals of the New York Academy of Sciences, June 1999, Wiley

    Professor Klaus Jung

  375. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA

    Article • Urology, June 1999, Elsevier

    Professor Klaus Jung

  376. Metalloproteinases and Tissue Inhibitors of Matrix-Metalloproteinases in Plasma of Patients with Prostate Cancer and in Prostate Cancer Tissue

    Article • Annals of the New York Academy of Sciences, June 1999, Wiley

    Professor Klaus Jung

  377. Metabolic Rates of 4-Hydroxynonenal in Tubular and Mesangial Cells of the Kidney

    Article • Nephron Experimental Nephrology, January 1999, Karger Publishers

    Professor Klaus Jung

  378. Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue

    Article • European Journal of Cancer, January 1999, Elsevier

    Professor Klaus Jung

  379. Rapid detection of elevated prostate-specific antigen levels in blood: performance of various membrane strip tests compared

    Article • Urology, January 1999, Elsevier

    Professor Klaus Jung

  380. Matrix metalloproteinases, but not cathepsins B, H, and L or their inhibitors in peripheral blood of patients with rheumatoid arthritis are potentially useful markers of disease activity

    Article • Zeitschrift für Rheumatologie, December 1998, Springer Science + Business Media

    Professor Klaus Jung

  381. Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer

    Article • International Journal of Cancer, October 1998, Wiley

    Professor Klaus Jung

  382. Plasma concentrations of metalloproteinases (MMP-1, MMP-3) and their inhibitors in patients with prostate cancer

    Article • Der Urologe, July 1998, Springer Science + Business Media

    Professor Klaus Jung

  383. RATIO OF FREE-TO-TOTAL PROSTATE SPECIFIC ANTIGEN IN SERUM CANNOT DISTINGUISH PATIENTS WITH PROSTATE CANCER FROM THOSE WITH CHRONIC INFLAMMATION OF THE PROSTATE

    Article • The Journal of Urology, May 1998, Wolters Kluwer Health

    Professor Klaus Jung

  384. Kind of Sample as Preanalytical Determinant of Matrix Metalloproteinases 2 and 9 and Tissue Inhibitor of Metalloproteinase 2 in Blood

    Article • Clinical Chemistry, May 1998, Oxford University Press (OUP)

    Professor Klaus Jung

  385. Periodate-oxidized ATP stimulates the permeability transition of rat liver mitochondria

    Article • Biochimica et Biophysica Acta (BBA) - Bioenergetics, March 1998, Elsevier

    Professor Klaus Jung

  386. Cathepsins B, H, L and cysteine proteinase inhibitors in renal cell carcinoma: no evidence for dysregulated proteolytic balance

    Article • Journal of Cancer Research and Clinical Oncology, February 1998, Springer Science + Business Media

    Professor Klaus Jung

  387. Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: Analytical aspects

    Article • The Prostate, February 1998, Wiley

    Professor Klaus Jung

  388. Relation of Free PSA/Total PSA in Serum for Differentiating Between Patients with Prostatic Cancer and Benign Hyperplasia of the Prostate: Which Cutoff Should Be Used?

    Article • Cancer Investigation, January 1998, Taylor & Francis

    Professor Klaus Jung

  389. Factors influencing the ratio of free to total prostate-specific antigen in serum

    Article • International Journal of Cancer, December 1997, Wiley

    Professor Klaus Jung

  390. Differential response of oxygen radical metabolism in rat heart, liver and kidney to cyclosporine A treatment

    Article • Inflammation Research, November 1997, Springer Science + Business Media

    Professor Klaus Jung

  391. Das Verhältnis freies PSA/Gesamt-PSA - eine Kenngröße zur Differenzierung zwischen Patienten mit Prostatakarzinom und benigner Prostatahyperplasie: Welcher Diskriminationspunkt sollte gewählt werden?

    Article • Aktuelle Urologie, November 1997, Thieme Publishing Group

    Professor Klaus Jung

  392. Betaine Improves the PCR Amplification of GC-Rich DNA Sequences

    Article • Nucleic Acids Research, October 1997, Oxford University Press (OUP)

    Professor Klaus Jung

  393. Plasma But Not Serum Should Be Used for Determining Tissue Inhibitor of Metalloproteinase in Blood

    Article • Alcoholism Clinical and Experimental Research, September 1997, Wiley

    Professor Klaus Jung

  394. Analytical Aspects Regarding the Measurement of Metalloproteinases and Their Inhibitors in Blood

    Article • Clinical Biochemistry, August 1997, Elsevier

    Professor Klaus Jung

  395. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer

    Article • International Journal of Cancer, April 1997, Wiley

    Professor Klaus Jung

  396. Re: Editorial: Can Prostate Specific Antigen Derivatives Reduce the Frequency of Unnecessary Prostate Biopsies?

    Article • The Journal of Urology, April 1997, Wolters Kluwer Health

    Professor Klaus Jung

  397. Increased analytical sensitivity of RT-PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood

    Article • International Journal of Cancer, January 1997, Wiley

    Professor Klaus Jung

  398. Antioxidant Enzymes In Malignant Prostate Cell Lines and In Primary Cultured Prostatic Cells

    Article • Free Radical Biology and Medicine, January 1997, Elsevier

    Professor Klaus Jung

  399. Effect of Starvation on Antioxidant Enzymes and Respiratory Mitochondrial Functions in Kidney and Liver from Rats.

    Article • Journal of Clinical Biochemistry and Nutrition, January 1997, The Society for Free Radical Research Japan

    Professor Klaus Jung

  400. Elimination of Serum Free and Total Prostate-Specific Antigen after Radical Retropubic Prostatectomy

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1997, De Gruyter

    Professor Klaus Jung

  401. Präanalytische und analytische Aspekte bei der Bestimmung von Metalloproteinasen und ihren Inhibitoren im Blut

    Article • LaboratoriumsMedizin, January 1997, De Gruyter

    Professor Klaus Jung

  402. Soluble CD44 Variants in the Serum of Patients with Urological Malignancies

    Article • Oncology, January 1997, Karger Publishers

    Professor Klaus Jung

  403. The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia

    Article • Cancer, January 1997, Wiley

    Professor Klaus Jung

  404. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells

    Article • Cancer, December 1996, Wiley

    Professor Klaus Jung

  405. Polymerase chain reaction in the detection of micrometastases and circulating tumor cells

    Article • Cancer, December 1996, Wiley

    Professor Klaus Jung

  406. Soluble CD44 variants in serum of patients with prostate cancer and other urological malignancies

    Article • The Prostate, November 1996, Wiley

    Professor Klaus Jung

  407. What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood?

    Article • Clinica Chimica Acta, October 1996, Elsevier

    Professor Klaus Jung

  408. Nonmhyperbolic calcium calibration curve of Fura-2: implications for the reliability of quantitative Ca2+ measurements

    Article • Cell Calcium, September 1996, Elsevier

    Professor Klaus Jung

  409. The ratio of free to total prostate-specific antigen in serum is correlated to the prostate volume

    Article • International Journal of Cancer, July 1996, Wiley

    Professor Klaus Jung

  410. Isoforms of prostate-specific antigen in serum: A result of the glycosylation process in dysplastic prostatic cells?

    Article • The Prostate, July 1996, Wiley

    Professor Klaus Jung

  411. Comparison between Equimolar- and Skewed-Response Assays of Prostate Specific Antigen: Is There an Influence on the Clinical Significance When Measuring Total Serum Prostate Specific Antigen?

    Article • Annals of Clinical Biochemistry International Journal of Laboratory Medicine, May 1996, SAGE Publications

    Professor Klaus Jung

  412. Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia

    Article • European Journal of Cancer, April 1996, Elsevier

    Professor Klaus Jung

  413. Developmental changes of antioxidant enzymes in kidney and liver from rats

    Article • Free Radical Biology and Medicine, January 1996, Elsevier

    Professor Klaus Jung

  414. TECHNICAL NOTE

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1996, De Gruyter

    Professor Klaus Jung

  415. Freies prostataspezifisches Antigen im Serum: eine Meßgröße zur Diskrimination zwischen Patienten mit Prostatakarzinom und benigner Prostatahyperplasie

    Article • LaboratoriumsMedizin, January 1996, De Gruyter

    Professor Klaus Jung

  416. Rapid screening of PSA: evaluation of an immunochemical membrane strip test

    Article • Clinical Chemistry, October 1995, Oxford University Press (OUP)

    Professor Klaus Jung

  417. Lower serum high-density lipoprotein-cholesterol concentration in patients undergoing maintenance hemodialysis with acetate than with bicarbonate

    Article • American Journal of Kidney Diseases, April 1995, Elsevier

    Professor Klaus Jung

  418. Culture of Human Kidney Proximal Tubular Cells – The Effect of Various Detachment Procedures on Viability and Degree of Cell Detachment

    Article • Cellular Physiology and Biochemistry, January 1995, Karger Publishers

    Professor Klaus Jung

  419. Cystatin C: A Promising Marker of Glomerular Filtration Rate to Replace Creatinine

    Article • Nephron, January 1995, Karger Publishers

    Professor Klaus Jung

  420. Prostataspezifisches Antigen (PSA): Einfluß des freien und gebundenen Anteils auf die klinische Aussagekraft als Tümormarker

    Article • LaboratoriumsMedizin, January 1995, De Gruyter

    Professor Klaus Jung

  421. Referenzbereiche der löslichen Adhäsionsmoleküle CD44 (Standard), CD44(v5) und CD44(v6) im Serum gesunder Erwachsener

    Article • LaboratoriumsMedizin, January 1995, De Gruyter

    Professor Klaus Jung

  422. Niedermolekulare Proteine im Serum als Marker der glomerulären Filtrationsrate: Cystatin C, α1-Mikroglobulin und ß2-Mikroglobulin

    Article • LaboratoriumsMedizin, January 1994, De Gruyter

    Professor Klaus Jung

  423. Changed excretion of urinary proteins and enzymes by chronic exposure to lead

    Article • Nephrology Dialysis Transplantation, January 1994, Oxford University Press (OUP)

    Professor Klaus Jung

  424. Nephron target sites in chronic exposure to lead

    Article • Nephrology Dialysis Transplantation, January 1994, Oxford University Press (OUP)

    Professor Klaus Jung

  425. Comparison of the effects of the immunosuppressive agents FK 506 and cyclosporin a on rat kidney mitochondria

    Article • Biochemical Pharmacology, September 1993, Elsevier

    Professor Klaus Jung

  426. Sandwich enzyme immunoassay of cystatin C in serum with commercially available antibodies

    Article • Clinical Chemistry, September 1993, Oxford University Press (OUP)

    Professor Klaus Jung

  427. What are the Criteria to Introduce New Methods for Determination of Urinary N-Acetyl-β-D-Glucosaminidase Activity?

    Article • Annals of Clinical Biochemistry International Journal of Laboratory Medicine, September 1993, SAGE Publications

    Professor Klaus Jung

  428. Excretion of Urinary Enzymes After Extracorporeal Shock Wave Lithotripsy: A Critical Reevaluation

    Article • The Journal of Urology, June 1993, Wolters Kluwer Health

    Professor Klaus Jung

  429. Effect of Storage Temperature on the Activity of Superoxide Dismutase, Catalase, Glutathione Peroxidase, Glutathione Reductase and Glutathione S-Transferase in Rat Liver and Kidney Homogenates

    Article • Enzyme and Protein, January 1993, Karger Publishers

    Professor Klaus Jung

  430. Cyclosporine a inhibits ATP net uptake of rat kidney mitochondria

    Article • Biochemical Pharmacology, March 1992, Elsevier

    Professor Klaus Jung

  431. Reference intervals for α1-microglobulin in urine

    Article • Clinica Chimica Acta, March 1992, Elsevier

    Professor Klaus Jung

  432. Osteocalcin und die Knochenfraktion der alkalischen Phosphatase im Serum nierentransplantierter Patienten

    Article • LaboratoriumsMedizin, January 1992, De Gruyter

    Professor Klaus Jung

  433. Sex- and Age-Dependent Reference Values of Alpha-1-Microglobulin in Urine

    Article • Nephron, January 1992, Karger Publishers

    Professor Klaus Jung

  434. A practical new assay for determining N-acetyl-β-D-glucosaminidase activity in urine

    Article • Clinica Chimica Acta, December 1991, Elsevier

    Professor Klaus Jung

  435. Review

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1991, De Gruyter

    Professor Klaus Jung

  436. Ischemia decreases the content of the adenine nucleotide translocator in mitochondria of rat kidney

    Article • Biochimica et Biophysica Acta (BBA) - Bioenergetics, January 1991, Elsevier

    Professor Klaus Jung

  437. Methods Compared for Determining Activity of N-Acetyl-β-D-Glucosaminidase in Urine without Pretreatment of Sample: Different Sensitivity and Species Effect

    Article • Enzyme, January 1991, Karger Publishers

    Professor Klaus Jung

  438. Ein kontinuierlicher Test zur Bestimmung der N-Acetyl-ß-D-glucosaminidase-Aktivität im Harn mit dem Substrat 3,3'-Dichlorphenol-sulfonphthaleinyl-N-acetyl-ß-D-glucosaminid: ein Vergleich mit anderen Methoden ohne Probenvorbereitung

    Article • LaboratoriumsMedizin, January 1991, De Gruyter

    Professor Klaus Jung

  439. Single-Injection Inulin Clearance Using Only One Blood Sample as a Suitable Procedure to Measure Glomerular Filtration Rate

    Article • Nephron, January 1991, Karger Publishers

    Professor Klaus Jung

  440. INFLUENCE OF PRESERVATION SOLUTIONS ON LIPID PEROXIDATION AND MITOCHONDRIAL RESPIRATION IN RAT KIDNEYS

    Article • Transplantation, May 1990, Wolters Kluwer Health

    Professor Klaus Jung

  441. IXHEMIA-INDUCED ALTERATIONS OF RAT KIDNEY MITOCHONDRIA

    Article • Transplantation, May 1990, Wolters Kluwer Health

    Professor Klaus Jung

  442. A microalbuminuria assay using bromphenol blue

    Article • Clinica Chimica Acta, February 1990, Elsevier

    Professor Klaus Jung

  443. Determination of purine compounds by ion-pair microbore high-performance liquid chromatography: application to ischemic rat kidney mitochondria

    Article • Journal of Chromatography B Biomedical Sciences and Applications, January 1990, Elsevier

    Professor Klaus Jung

  444. How should we measure activity of alanine aminopeptidase in urine?

    Article • Clinical Chemistry, January 1990, Oxford University Press (OUP)

    Professor Klaus Jung

  445. Refinements of Assays for Low Concentrations of Inulin in Serum

    Article • Nephron, January 1990, Karger Publishers

    Professor Klaus Jung

  446. Urinary Enzyme Excretion after Donor Nephrectomy – How Should We Express and Compare Excretion Rates of the Remaining Kidney after Donor Nephrectomy?

    Article • Nephron, January 1990, Karger Publishers

    Professor Klaus Jung

  447. Measurement of lysozyme in human body fluids: Comparison of various enzyme immunoassay techniques and their diagnostic application

    Article • Clinical Biochemistry, October 1989, Elsevier

    Professor Klaus Jung

  448. Adenosine formation by isolated rat kidney mitochondria

    Article • FEBS Letters, August 1989, Wiley

    Professor Klaus Jung

  449. Further evidence for tubular dysfunction in insulin dependent diabetes

    Article • Journal of Diabetic Complications, July 1989, Elsevier

    Professor Klaus Jung

  450. CLASS II ANTIGEN EXPRESSION BY KERATINOCYTES AND ENTEROCYTES—AN EARLY FEATURE OF GRAFT-VERSUS-HOST-DISEASE

    Article • Transplantation, September 1988, Wolters Kluwer Health

    Professor Klaus Jung

  451. CHANGED COMPOSITION OF HIGH-DENSITY LIPOPROTEIN SUBCLASSES HDL2 AND HDL3 AFTER RENAL TRANSPLANTATION

    Article • Transplantation, September 1988, Wolters Kluwer Health

    Professor Klaus Jung

  452. Diuresis-dependent excretions of low-molecular mass proteins in urine: β2-microglobulin, lysozyme, and ribonuclease

    Article • Scandinavian Journal of Clinical and Laboratory Investigation, January 1988, Taylor & Francis

    Professor Klaus Jung

  453. Quality control material for activity determinations of urinary enzymes

    Article • Clinical Biochemistry, January 1988, Elsevier

    Professor Klaus Jung

  454. Diagnostic significance of different urinary enzymes in patients suffering from chronic renal diseases

    Article • Clinica Chimica Acta, October 1987, Elsevier

    Professor Klaus Jung

  455. 31P-NMR spectroscopy and ultrastructural studies on nephrotoxicity of cyclosporine A

    Article • Experimental Pathology, January 1987, Elsevier

    Professor Klaus Jung

  456. Diagnostic Value of Low-Molecular Mass Proteins in Serum for the Detection of Reduced Glomerular Filtration Rate

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1987, De Gruyter

    Professor Klaus Jung

  457. Harnenzyme im Experiment und in der Klinik. Bericht über ein Symposium der Humboldt-Universität Berlin und des Bezirkskrankenhauses Frankfurt/Oder in Frankfurt/Oder (DDR), 22.-25. 4. 1987

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1987, De Gruyter

    Professor Klaus Jung

  458. Low-Molecular-Mass Proteins in Serum and Their Relationship to the Glomerular Filtration Rate

    Article • Nephron, January 1987, Karger Publishers

    Professor Klaus Jung

  459. Specific Creatinine Determination in Laboratory Animals Using the New Enzymatic Test Kit “Creatinine-PAP”

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1987, De Gruyter

    Professor Klaus Jung

  460. Inhibited Efficiency of Kidney Mitochondria Isolated from Rats Treated with Cyclosporin A

    Article • Nephron, January 1987, Karger Publishers

    Professor Klaus Jung

  461. Diuresis-dependent excretion of multiple forms of renal brush-border enzymes in urine

    Article • Clinica Chimica Acta, April 1986, Elsevier

    Professor Klaus Jung

  462. An Optimized Micromethod for Determining the Catalytic Activity of Serum Ribonuclease

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1986, De Gruyter

    Professor Klaus Jung

  463. Changed enzyme activities in rat kidney during ischemia

    Article • Journal of Surgical Research, November 1985, Elsevier

    Professor Klaus Jung

  464. Diagnostic significance of urinary enzymes in detecting acute rejection crises in renal transplant recipients depending on expression of results illustrated through the example of alanine aminopeptidase

    Article • Clinical Biochemistry, August 1985, Elsevier

    Professor Klaus Jung

  465. Influence of cyclosporin A on the respiration of isolated rat kidney mitochondria

    Article • FEBS Letters, April 1985, Wiley

    Professor Klaus Jung

  466. Phosphatidic acid phosphatase activity in subcellular fractions of normal and dystrophic human muscle

    Article • Clinica Chimica Acta, March 1985, Elsevier

    Professor Klaus Jung

  467. Increased serum γ-glutamyltransferase activity in renal transplant recipients: liver damage or microsomal enzyme induction?

    Article • Clinica Chimica Acta, August 1984, Elsevier

    Professor Klaus Jung

  468. Long-Term Stability of Enzymes in Human Serum Stored in Liquid Nitrogen

    Article • Enzyme, January 1984, Karger Publishers

    Professor Klaus Jung

  469. Multiple Forms of Alanine Aminopeptidase, Alkaline Phosphatase and γ-Glutamyltransferase in Urine of Healthy Persons, Patients Suffering from Kidney Diseases and Patients with Kidney Transplants

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1984, De Gruyter

    Professor Klaus Jung

  470. Stability of enzymes in urine at 37°C

    Article • Clinica Chimica Acta, July 1983, Elsevier

    Professor Klaus Jung

  471. LecithiniCholesterol Acyltransferase Activity and HDL Composition in Serum of Patients with Kidney Transplants

    Article • Enzyme, January 1983, Karger Publishers

    Professor Klaus Jung

  472. Suitability of commercial control sera for the quality control of activity determination of gamma-glutamyl transferase

    Article • Clinica Chimica Acta, April 1982, Elsevier

    Professor Klaus Jung

  473. On the pyridoxal-5′-phosphate stimulation of aspartate aminotransferase and alanine aminotransferase in serum and erythrocytes of patients undergoing chronic haemodialysis and with kidney transplants

    Article • Clinica Chimica Acta, September 1981, Elsevier

    Professor Klaus Jung

  474. On the validity of a levo-norgestrel radioimmunoassay

    Article • Clinica Chimica Acta, January 1981, Elsevier

    Professor Klaus Jung

  475. Influence of inorganic phosphate on the activity determination of isoenzymes of alkaline phosphatase in various buffer systems

    Article • Clinica Chimica Acta, March 1980, Elsevier

    Professor Klaus Jung

  476. On the influence of reaction conditions in activity determination of alkaline phosphatase on the molar absorptivity of 4-nitrophenol

    Article • Clinica Chimica Acta, February 1980, Elsevier

    Professor Klaus Jung

  477. Increased Creatine Kinase BB Activity in Rat Plasma Induced by Hypoxia

    Article • Enzyme, January 1980, Karger Publishers

    Professor Klaus Jung

  478. Lecithin: Cholesterol Acyltransferase Activity, HDL-Cholesterol and Apolipoprotein A in Serum of Patients Undergoing Chronic Haemodialysis

    Article • Enzyme, January 1980, Karger Publishers

    Professor Klaus Jung

  479. Suitability of commercial control sera for the quality control of activity determination of alkaline phosphatase

    Article • Clinica Chimica Acta, October 1979, Elsevier

    Professor Klaus Jung

  480. Creatine kinase isoenzyme BB in serum of healthy adults and children

    Article • Clinica Chimica Acta, January 1979, Elsevier

    Professor Klaus Jung

  481. Creatine Kinase Isoenzyme BB in Serum of Patients undergoing Chronic Hemodialysis and with Kidney Transplant

    Article • Enzyme, January 1979, Karger Publishers

    Professor Klaus Jung

  482. Influence of Mg^2+ Ions on the Activity Measurement of Isoenzymes of Alkaline Phosphatase

    Article • Enzyme, January 1979, Karger Publishers

    Professor Klaus Jung

  483. Stability of Isoenzymes of Alkaline Phosphatase in Various Buffer Systems

    Article • Enzyme, January 1979, Karger Publishers

    Professor Klaus Jung

  484. The apoenzyme of aspartate aminotransferase and alanine aminotransferase in the serum of healthy persons and patients suffering from liver diseases

    Article • Clinica Chimica Acta, December 1978, Elsevier

    Professor Klaus Jung

  485. Influence of Monoethanolamine on Activity Measurements of the Isoenzymes of Alkaline Phosphatase

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1978, De Gruyter

    Professor Klaus Jung

  486. Lecithin: Cholesterol Acyltransferase Activity in Patients with Chronic Liver Diseases and Positive LP-X Tests

    Article • Digestion, January 1978, Karger Publishers

    Professor Klaus Jung

  487. Relative Stimulation of Aspartate Aminotransferase Activity in Human Serum by Pyridoxal 5'-Phosphate in Myocardial Infarction

    Article • Enzyme, January 1978, Karger Publishers

    Professor Klaus Jung

  488. Comparative determinations of aminotransferase activities in serum with so-called “optimised” methods

    Article • Clinica Chimica Acta, December 1977, Elsevier

    Professor Klaus Jung

  489. Suitability of commercial enzyme control sera for the quality control of activity determinations of l-aspartate aminotransferase and l-alanine aminotransferase in human serum

    Article • Clinica Chimica Acta, September 1977, Elsevier

    Professor Klaus Jung

  490. Exchange of different phosphatidylcholine molecular species by phospholipid exchange protein of rat liver

    Article • FEBS Letters, March 1977, Wiley

    Professor Klaus Jung

  491. Pyridoxal 5’-phosphate as an Activator of the Apoenzyrne of Alanine Aminotransferase in Human Serum

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1977, De Gruyter

    Professor Klaus Jung

  492. Influence of Auxiliary Enzymes on the Spectrophotometric Measurement of Alanine Aminotransferase and Aspartate Aminotransferase Activities

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1976, De Gruyter

    Professor Klaus Jung

  493. Effect of pyridoxal 5′-phosphate on the temperature relationships of alanine aminotransferase

    Article • Clinica Chimica Acta, November 1975, Elsevier

    Professor Klaus Jung

  494. Der Einfluß von Pyridoxal-5’-phosphat auf das Temperaturverhalten der Aspartataminotransferase-Isoenzyme

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1975, De Gruyter

    Professor Klaus Jung

  495. Zum Einfluß der Temperatur auf Enzymaktivitätsbestimmungen im Serum: Glutamatdehydrogenase

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1974, De Gruyter

    Professor Klaus Jung

  496. KURZMITTEILUNG

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1973, De Gruyter

    Professor Klaus Jung

  497. SHORT COMMUNICATION

    Article • Hoppe-Seyler´s Zeitschrift für physiologische Chemie, January 1973, De Gruyter

    Professor Klaus Jung

  498. Ein farbtest zur bestimmung der glutamatdehydrogenase-aktivität im serum

    Article • Clinica Chimica Acta, January 1972, Elsevier

    Professor Klaus Jung

  499. KURZMITTEILUNG

    Article • Clinical Chemistry and Laboratory Medicine (CCLM), January 1972, De Gruyter

    Professor Klaus Jung

  500. An Optimized Assay of Human Serum Glutamate Dehydrogenase Activity

    Article • Enzyme, January 1972, Karger Publishers

    Professor Klaus Jung

  501. Zur Problematik der Chemo-Taxonomie von Protozoen

    Article • Zeitschrift für allgemeine Mikrobiologie, January 1970, Wiley

    Professor Klaus Jung